Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.

SnapShot: broadly neutralizing antibodies.

A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.

Broadly neutralizing antibodies against the rapidly evolving porcine reproductive and respiratory syndrome virus.

Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance.

Broadly neutralizing antibodies abrogate established hepatitis C virus infection.

Natural evolution of broadly neutralizing antibodies.

HIV vaccine development and broadly neutralizing antibodies.

Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.

Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.

A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies.

Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir.

Approaches to the induction of HIV broadly neutralizing antibodies.

Potent neutralizing monoclonal antibodies against Ebola virus infection.

Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies.

Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.

A broadly neutralizing human monoclonal antibody is effective against H7N9.

Influenza virus antigenicity and broadly neutralizing epitopes.

Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.

Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies.

Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.

Identification and specificity of broadly neutralizing antibodies against HIV.

Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus.

Prediction of optimal peptide mixtures to induce broadly neutralizing antibodies to human immunodeficiency virus type 1.

In vivo protection by broadly neutralizing HIV antibodies.

Suggest Documents

SnapShot: broadly neutralizing antibodies.

A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.

Broadly neutralizing antibodies against the rapidly evolving porcine reproductive and respiratory syndrome virus.

Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance.

Broadly neutralizing antibodies abrogate established hepatitis C virus infection.

Natural evolution of broadly neutralizing antibodies.

HIV vaccine development and broadly neutralizing antibodies.

Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.

Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.

A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies.

Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir.

Approaches to the induction of HIV broadly neutralizing antibodies.

Potent neutralizing monoclonal antibodies against Ebola virus infection.

Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies.

Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.

A broadly neutralizing human monoclonal antibody is effective against H7N9.

Influenza virus antigenicity and broadly neutralizing epitopes.

Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.

Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies.

Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.

Identification and specificity of broadly neutralizing antibodies against HIV.

Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus.

Prediction of optimal peptide mixtures to induce broadly neutralizing antibodies to human immunodeficiency virus type 1.

In vivo protection by broadly neutralizing HIV antibodies.

Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.

Recommend Documents

Follow Us